Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial.
The post With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond appeared first on MedCity News.
